Anthony DeFino; Arshad Khanani, MD, MA, FASRS , 2025-05-12 19:40:00
Key takeaways:
- The meeting will take place June 21 in Las Vegas.
- Attendees will explore topics such as regulatory considerations for pivotal trial design and AI in imaging and clinical development.
Clinical Trials at the Summit will be held Saturday, June 21, at Fontainebleau Las Vegas.
The meeting will focus on the latest data in vitreoretinal care from ongoing clinical trials. Through an emphasis on relationship building, the meeting will explore strategies to design and execute effective clinical trials.
Healio spoke with Arshad M. Khanani, MD, MA, FASRS, founder and co-chair of Clinical Trials at the Summit (CTS), about the meeting’s growth since its debut in 2021 and the key topics that will be of interest to retina experts from around the world.
Healio: As the founder of CTS, what did you hope to accomplish with this meeting?
Khanani: CTS was established to bring together all key stakeholders involved in drug development, including retina experts, sponsors, contract research organizations, clinical sites and investors, with the goal of designing and executing trials more efficiently to deliver new treatment options to patients faster.
Healio: How has the meeting grown over the years?
Khanani: Since its inception in 2021, CTS has experienced exponential growth and is now recognized as one of the most important meetings focused on clinical trials in retina.
In previous years, CTS was exclusively invite only for faculty. This year, we have opened a dedicated track for invited non-faculty retina specialists to attend. This allows more clinicians to engage with the latest developments and build meaningful connections with leading stakeholders in the field.
Healio: What hot topics will be at the forefront of the meeting this year?
Khanani: A major highlight will be the unveiling of first-time clinical trial results from significant 2025 data readouts, offering valuable insights into the future of retina therapeutics.
Additionally, the program will feature a range of informative sessions covering topics such as the application of AI in imaging and clinical development, regulatory considerations for pivotal trial design, the promise of gene therapy and tyrosine kinase inhibitors in treating retinal vascular diseases, and the role of imaging endpoints in geographic atrophy trials.
Healio: Outside of the sessions, are there any special events that attendees can look forward to?
Khanani: As an invite-only meeting, CTS offers unique value through informal yet impactful hallway conversations. These interactions provide a rare opportunity to network, reconnect with colleagues and meet new peers who share a commitment to advancing retina research.
For more information:
Arshad M. Khanani, MD, MA, FASRS, of Sierra Eye Associates in Reno, Nevada, can be reached at arshad.khanani@gmail.com.
Meeting information can be found at https://www.ctsretina.org/.
Sources/Disclosures
Collapse
Healio Interviews
Disclosures:
Khanani reports being co-chair and founder of Clinical Trials at the Summit.
